Page 9 - Flipbook

Treatment intensification in mCSPC

1. List the clinical benefits of systemic

treatments for mCSPC/mCNPC,

including docetaxel,

abiraterone/prednisone, and

Learning Objectives androgen receptor–targeted

agents

2. Define when docetaxel should be

considered as upfront therapy

mCSPC, metastatic castrate-sensitive prostate cancer; mCNPC, metastatic castrate-naïve prostate cancer